DuPont Decomposition

Why does SHILPAMED earn its ROE?

Breaking down Return on Equity into profitability, efficiency, and leverage.

ROE = Net Margin × Asset Turnover × Equity Multiplier

3.3% = 6.1% × 0.39 × 1.40

Latest: FY2025

Profitability

Net Margin

6.1%

5.3% →6.1%

How much profit per ₹ of revenue

Efficiency

Asset Turnover

0.39x

0.40x →0.39x

Revenue per ₹ of assets

Leverage

Equity Multiplier

1.40x

1.58x →1.40x

Assets funded by equity vs debt

Trend Analysis

ROE stable at ~3%.

Historical Decomposition

Last 4 years

YearRevenuePATNet MarginAsset TOLeverageROE
FY20220Cr0Cr5.3%0.401.583.3%
FY20230Cr-0Cr-3.1%0.361.63-1.8%
FY20240Cr0Cr2.8%0.371.721.8%
FY20250Cr0Cr6.1%0.391.403.3%

How to read DuPont

  • Rising ROE from margin = pricing power, operational improvement (good)
  • Rising ROE from turnover = better asset utilization (good)
  • Rising ROE from leverage = more debt, amplified risk (caution)
  • Falling ROE across all three = structural deterioration (red flag)

See DCF fair value for SHILPAMED

Combine financial quality with intrinsic value.

See Fair Value →

DuPont decomposition from audited annual financials. Factual analysis, not investment advice.

SHILPAMED DuPont Analysis — ROE 3.3% | YieldIQ